Отчеты об исследованиях щитовидной железы

Hyperthyroidism is a common endocrine disorder characterized by an excess of thyroid hormone production. While conventional treatment options such as antithyroid drugs, radioactive iodine therapy, and surgery are effective, they can be associated with side effects and may not address underlying dysregulation of the gut microbiota observed in hyperthyroid patients. Probiotic microbial strains have emerged as a potential adjunctive therapy for hyperthyroidism due to their ability to modulate gut microbiota composition and function. This article reviews the current understanding of neuro-hormonal dynamics in hyperthyroidism and the potential impact of probiotic microbial strains on these dynamics, focusing on findings from a murine model of hyperthyroidism. Hyperthyroidism is a condition characterized by elevated levels of thyroid hormones, primarily thyroxine and triiodothyronine, which are produced by the thyroid gland.

Hyperthyroidism is a common endocrine disorder characterized by an excess of thyroid hormone production. While conventional treatment options such as antithyroid drugs, radioactive iodine therapy, and surgery are effective, they can be associated with side effects and may not address underlying dysregulation of the gut microbiota observed in hyperthyroid patients. Probiotic microbial strains have emerged as a potential adjunctive therapy for hyperthyroidism due to their ability to modulate gut microbiota composition and function. This article reviews the current understanding of neuro-hormonal dynamics in hyperthyroidism and the potential impact of probiotic microbial strains on these dynamics, focusing on findings from a murine model of hyperthyroidism. Hyperthyroidism is a condition characterized by elevated levels of thyroid hormones, primarily thyroxine and triiodothyronine, which are produced by the thyroid gland. The condition is often caused by Graves' disease, an autoimmune disorder, or by nodules on the thyroid gland that produce excess hormone. Hyperthyroidism can lead to a variety of symptoms, including weight loss, increased heart rate, tremors, and anxiety. Conventional treatments for hyperthyroidism aim to reduce thyroid hormone levels and may include antithyroid drugs, radioactive iodine therapy, or surgery. However, these treatments can be associated with side effects and may not address the underlying dysregulation of the gut microbiota observed in hyperthyroid patients.

Thyroid eye disease, also known as Graves' orbitopathy, is an autoimmune condition characterized by inflammation and swelling of the tissues around the eyes. The disease can cause significant morbidity and affect the quality of life of affected individuals. In recent years, several advancements have been made in the management of TED, including the development of new treatment modalities and the repurposing of existing medications. This article reviews one significant advancement in the treatment of TED, the use of teprotumumab, and one incremental step forward in the use of doxycycline, an existing medication with potential benefits in TED management. The treatment landscape for Thyroid Eye Disease has evolved significantly, with advancements like Teprotumumab offering new hope for patients. This biologic has set a new standard for efficacy in reducing proptosis and improving eye function in TED patients.

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) are widely used in the management of type 2 diabetes due to their glucose-lowering effects and favorable safety profile. However, emerging evidence suggests that GLP-1 RAs may also have a dual role in prostate cancer, with both beneficial and potentially harmful effects. This article provides an overview of the current understanding of the dual role of GLP-1 RAs in prostate cancer, highlighting their potential as a therapeutic target in oncology.